Vaccine company NeoVac has taken lab and office space at Milton Park for its team of more than 20.
The move to 127 Olympic Avenue is intended to allow the firm to grow and capitalise on future opportunities.
NeoVac, a spinout from Tel Aviv University, was founded in 2021 by scientists Prof Dan Peer and Professor Sir Adrian Hill the co-inventor of the, now withdrawn, AstraZeneca Covid vaccine.
Tom Booker, commercial manager at MEPC Milton Park, said: “It’s been a pleasure to work with NeoVac to meet their space and fit-out requirements, giving them the flexibility and peace-of-mind to focus on providing people around the world with access to better vaccines and treatments.
“Joining the likes of Immunocore, Exscientia and Evotec, NeoVac is a valued addition to Milton Park’s thriving biotech cluster. We look forward to watching their progress as they go from strength to strength.”
NeoVac chief executive Dr Eran Eilat, said: “As NeoVac grew to what is now over 20 team members we needed to find new premises which gave us flexibility and opportunities to scale as we continue our mission to revolutionise LNP-mRNA based vaccines and treatments around the globe.
“Receiving dedicated support from Tom (Booker) and the MEPC team, our move to Milton Park was fast and seamless and included an extensive fit-out, complete with offices, advanced labs and ducted chemical hoods, which is very hard to come by in Oxfordshire.
“Benefitting from its close proximity to Oxford, Milton Park gives us a platform to collaborate with leading life science companies and gain access to world-class talent and universities. We’re looking forward to integrating with the wider Milton Park community as we begin life at our new HQ.”
© Thames Tap (powered by ukpropertyforums.com).
Sign up to receive our weekly free journal, The Forum here.
